Drugmaker AstraZeneca Pharma India Ltd. on Thursday said it will launch its Acalabrutinib 100 milligram capsules, used for treatment of various types of blood cancers, under the brand name 'Calquence' in the country on Oct. 21.
The capsules are indicated for treatment of patients with mantle cell lymphoma who have received at least one prior therapy and for treatment of patients with chronic lymphocytic leukaemia and small lymphocytic lymphoma, AstraZeneca Pharma India said in a filing to the stock exchanges.
Shares of AstraZeneca Pharma India Ltd. on Thursday closed 0.61% lower at Rs 4,266.65 apiece on the BSE.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
